# Isabella Bank Corp: financial statements, quarterly

ISBA · Nasdaq · CIK 842517 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/isba.md) · [Financials](/companies/isba/financials.md) · [Filings](/companies/isba/filings.md) · [Insiders](/companies/isba/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/isba/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $k | [6,183](/filings/0000842517-24-000201.md) | [7,444 d](/filings/0000842517-24-000048.md) | [8,138](/filings/0000842517-24-000088.md) | [8,538](/filings/0000842517-24-000146.md) | [8,853](/filings/0000842517-24-000201.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [937](/filings/0000842517-23-000186.md) | [726 d](/filings/0000842517-26-000069.md) | [511](/filings/0000842517-24-000088.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [4,413](/filings/0000842517-24-000201.md) | [3,803 d](/filings/0000842517-26-000069.md) | [3,131](/filings/0000842517-25-000099.md) | [3,481](/filings/0000842517-25-000135.md) | [3,281](/filings/0000842517-25-000210.md) | [3,996 d](/filings/0000842517-26-000069.md) | [3,949](/filings/0000842517-26-000099.md) | [5,031](/filings/0000842517-26-000180.md) | [5,240](/filings/0000842517-25-000210.md) | [4,690 d](/filings/0000842517-26-000069.md) | [4,992](/filings/0000842517-26-000099.md) | [5,041](/filings/0000842517-26-000180.md) |
| Diluted EPS | $ per share | [0.58](/filings/0000842517-24-000201.md) | not reported | [0.42](/filings/0000842517-25-000099.md) | [0.46](/filings/0000842517-25-000135.md) | [0.44](/filings/0000842517-25-000210.md) | not reported | [0.53](/filings/0000842517-26-000099.md) | [0.68](/filings/0000842517-26-000180.md) | [0.71](/filings/0000842517-25-000210.md) | not reported | [0.68](/filings/0000842517-26-000099.md) | [0.69](/filings/0000842517-26-000180.md) |
| Basic EPS | $ per share | [0.59](/filings/0000842517-24-000201.md) | not reported | [0.42](/filings/0000842517-25-000099.md) | [0.47](/filings/0000842517-25-000135.md) | [0.44](/filings/0000842517-25-000210.md) | not reported | [0.53](/filings/0000842517-26-000099.md) | [0.68](/filings/0000842517-26-000180.md) | [0.71](/filings/0000842517-25-000210.md) | not reported | [0.68](/filings/0000842517-26-000099.md) | [0.69](/filings/0000842517-26-000180.md) |

- Revenue: not reported
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [116](/filings/0000842517-23-000186.md) | [33.7](/filings/0000842517-25-000053.md) | [25.2](/filings/0000842517-24-000088.md) | [23.6](/filings/0000842517-24-000146.md) | [27.4](/filings/0000842517-24-000201.md) | [24.5](/filings/0000842517-26-000069.md) | [69.2](/filings/0000842517-25-000099.md) | [109](/filings/0000842517-25-000135.md) | [161](/filings/0000842517-25-000210.md) | [26.0](/filings/0000842517-26-000180.md) | [50.1](/filings/0000842517-26-000099.md) | [41.8](/filings/0000842517-26-000180.md) |
| Total assets | $m | [2,118](/filings/0000842517-23-000186.md) | [2,059](/filings/0000842517-25-000053.md) | [2,058](/filings/0000842517-24-000088.md) | [2,060](/filings/0000842517-24-000146.md) | [2,107](/filings/0000842517-24-000201.md) | [2,086](/filings/0000842517-26-000069.md) | [2,103](/filings/0000842517-25-000099.md) | [2,156](/filings/0000842517-25-000135.md) | [2,260](/filings/0000842517-25-000210.md) | [2,209](/filings/0000842517-26-000180.md) | [2,252](/filings/0000842517-26-000099.md) | [2,220](/filings/0000842517-26-000180.md) |
| Total liabilities | $m | [1,933](/filings/0000842517-23-000186.md) | [1,857](/filings/0000842517-25-000053.md) | [1,857](/filings/0000842517-24-000088.md) | [1,858](/filings/0000842517-24-000146.md) | [1,894](/filings/0000842517-24-000201.md) | [1,876](/filings/0000842517-26-000069.md) | [1,887](/filings/0000842517-25-000099.md) | [1,936](/filings/0000842517-25-000135.md) | [2,032](/filings/0000842517-25-000210.md) | [1,978](/filings/0000842517-26-000180.md) | [2,018](/filings/0000842517-26-000099.md) | [1,971](/filings/0000842517-26-000180.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [185](/filings/0000842517-24-000201.md) | [202](/filings/0000842517-26-000069.md) | [201](/filings/0000842517-25-000135.md) | [202](/filings/0000842517-25-000210.md) | [213](/filings/0000842517-25-000210.md) | [210](/filings/0000842517-26-000180.md) | [216](/filings/0000842517-26-000180.md) | [221](/filings/0000842517-26-000180.md) | [227](/filings/0000842517-25-000210.md) | [231](/filings/0000842517-26-000180.md) | [234](/filings/0000842517-26-000180.md) | [249](/filings/0000842517-26-000180.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [3.8 d](/filings/0000842517-24-000201.md) | [5.4 d](/filings/0000842517-26-000069.md) | [3.4](/filings/0000842517-25-000099.md) | [5.5 d](/filings/0000842517-25-000135.md) | [3.6 d](/filings/0000842517-25-000210.md) | [7.1 d](/filings/0000842517-26-000069.md) | [4.6](/filings/0000842517-26-000099.md) | [7.8 d](/filings/0000842517-26-000180.md) | [2.9 d](/filings/0000842517-25-000210.md) | [11.5 d](/filings/0000842517-26-000069.md) | [3.8](/filings/0000842517-26-000099.md) | [7.7 d](/filings/0000842517-26-000180.md) |
| Capital expenditure | $m | [1.1 d](/filings/0000842517-24-000201.md) | [1.2 d](/filings/0000842517-26-000069.md) | [0.8](/filings/0000842517-25-000099.md) | [0.4 d](/filings/0000842517-25-000135.md) | [0.4 d](/filings/0000842517-25-000210.md) | [0.5 d](/filings/0000842517-26-000069.md) | [1.0](/filings/0000842517-26-000099.md) | [0.6 d](/filings/0000842517-26-000180.md) | [1.0 d](/filings/0000842517-25-000210.md) | [0.9 d](/filings/0000842517-26-000069.md) | [0.5](/filings/0000842517-26-000099.md) | [0.4 d](/filings/0000842517-26-000180.md) |
| Dividends paid | $m | [2.1 d](/filings/0000842517-24-000201.md) | [2.1 d](/filings/0000842517-26-000069.md) | [2.1](/filings/0000842517-25-000099.md) | [2.0 d](/filings/0000842517-25-000135.md) | [2.0 d](/filings/0000842517-25-000210.md) | [2.0 d](/filings/0000842517-26-000069.md) | [2.0](/filings/0000842517-26-000099.md) | [2.0 d](/filings/0000842517-26-000180.md) | [2.0 d](/filings/0000842517-25-000210.md) | [2.0 d](/filings/0000842517-26-000069.md) | [2.1](/filings/0000842517-26-000099.md) | [2.0 d](/filings/0000842517-26-000180.md) |
| Share repurchases | $m | [0.5 d](/filings/0000842517-24-000201.md) | [0.5 d](/filings/0000842517-26-000069.md) | [0.7](/filings/0000842517-25-000099.md) | [0.7 d](/filings/0000842517-25-000135.md) | [1.0 d](/filings/0000842517-25-000210.md) | [0.7 d](/filings/0000842517-26-000069.md) | [1.1](/filings/0000842517-26-000099.md) | [1.5 d](/filings/0000842517-26-000180.md) | [0.6 d](/filings/0000842517-25-000210.md) | [1.5 d](/filings/0000842517-26-000069.md) | [0.4](/filings/0000842517-26-000099.md) | [0.2 d](/filings/0000842517-26-000180.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [7,651](/filings/0000842517-23-000186.md) | [7,634](/filings/0000842517-24-000088.md) | [7,568](/filings/0000842517-24-000146.md) | [7,570](/filings/0000842517-24-000201.md) | [7,508](/filings/0000842517-25-000099.md) | [7,495](/filings/0000842517-25-000135.md) | [7,473](/filings/0000842517-25-000210.md) | [7,432](/filings/0000842517-26-000099.md) | [7,398](/filings/0000842517-26-000180.md) | [7,372](/filings/0000842517-25-000210.md) | [7,329](/filings/0000842517-26-000099.md) | [7,337](/filings/0000842517-26-000180.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 7,628,873 at 2026-08-06, from the cover of the [10-Q filed 2026-08-10](/filings/0000842517-26-000180.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.